Literature DB >> 15363818

Tissue inhibitor of metalloproteinase-1 and matrix metalloproteinase-9 levels in patients with hypertension Relationship to tissue Doppler indices of diastolic relaxation.

Muzahir H Tayebjee1, Sunil K Nadar, Robert J MacFadyen, Gregory Y H Lip.   

Abstract

BACKGROUND: Hypertension, hypertensive heart disease, and left ventricular (LV) hypertrophy are integral to symptomatic diastolic heart failure. Tissue inhibitor of metalloproteinase-1 (TIMP-1) is linked to extracellular matrix fibrosis and is elevated in hypertension. We hypothesized a link between circulating TIMP-1, matrix metalloproteinase-9 (MMP-9), and resting echocardiographic LV filling parameters using tissue Doppler parameters of diastolic (dys)function.
METHODS: Circulating MMP-9 and TIMP-1 levels were measured in citrated plasma by ELISA in 74 patients with hypertension (58 men, mean age 58 +/- 11 years) and 34 controls (23 men, mean age 53 +/- 13 years). All had confirmed normal short axis systolic contractility, with no significant wall motion abnormalities; the LV mass and standard resting tissue Doppler echocardiographic indices of diastolic function were also recorded.
RESULTS: Both MMP-9 and TIMP-1 levels were higher in the hypertensive group (P =.0039 and P =.0054, respectively). When compared to controls, hypertensive patients had a greater LV mass (P =.0054), and differences in many of the parameters reflecting diastolic dysfunction (controls versus hypertensives: E: 0.71 +/- 0.15 v 0.81 +/- 0.15 m/sec, P =.004; A: 0.66 +/- 0.12 v 0.81 +/- 0.16 m/sec, P <.0001; e': 0.12 (0.09-0.14) v 0.09 (0.07-0.10) m/sec, P =.0017; e'/a': 1.20 (1.00-1.80) v 0.88 (0.71-1.05), P <.0001; E/e': 6.54 (4.75-7.14) v 8.89 (7.55-10.75), P <.0001, respectively). Within the hypertensive cohort, only TIMP-1 levels correlated with LV mass (r = 0.271, P =.024), LV mass index (r = 0.323, P =.007), and tissue Doppler parameters of diastolic dysfunction, including e' (r = -0.338, P =.005), a' (r = -0.350, P =.005), and E/e' (r = 0.334, P =.005).
CONCLUSIONS: TIMP-1 is thought to increase tissue concentrations of collagen type I by preventing its breakdown by MMPs. Our findings therefore add weight to a hypothesis suggesting that TIMP-1 may be a key mediator of LV diastolic dysfunction through definition of ventricular matrix composition. Copyright 2004 American Journal of Hypertension, Ltd.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15363818     DOI: 10.1016/j.amjhyper.2004.06.023

Source DB:  PubMed          Journal:  Am J Hypertens        ISSN: 0895-7061            Impact factor:   2.689


  29 in total

1.  Elevated circulating levels of matrix metalloproteinases MMP-2 and MMP-9 in pseudoxanthoma elasticum patients.

Authors:  Ulf Diekmann; Ralf Zarbock; Doris Hendig; Christiane Szliska; Knut Kleesiek; Christian Götting
Journal:  J Mol Med (Berl)       Date:  2009-07-03       Impact factor: 4.599

2.  Matrix metalloproteinases and cardiovascular diseases.

Authors:  A Papazafiropoulou; N Tentolouris
Journal:  Hippokratia       Date:  2009-04       Impact factor: 0.471

3.  Plasma biomarkers that reflect determinants of matrix composition identify the presence of left ventricular hypertrophy and diastolic heart failure.

Authors:  Michael R Zile; Stacia M Desantis; Catalin F Baicu; Robert E Stroud; Sheila B Thompson; Catherine D McClure; Shannon M Mehurg; Francis G Spinale
Journal:  Circ Heart Fail       Date:  2011-02-24       Impact factor: 8.790

Review 4.  The Roles of Matrix Metalloproteinases and Their Inhibitors in Human Diseases.

Authors:  Griselda A Cabral-Pacheco; Idalia Garza-Veloz; Claudia Castruita-De la Rosa; Jesús M Ramirez-Acuña; Braulio A Perez-Romero; Jesús F Guerrero-Rodriguez; Nadia Martinez-Avila; Margarita L Martinez-Fierro
Journal:  Int J Mol Sci       Date:  2020-12-20       Impact factor: 5.923

Review 5.  Changes in the myocardial interstitium and contribution to the progression of heart failure.

Authors:  Shaina R Eckhouse; Francis G Spinale
Journal:  Heart Fail Clin       Date:  2012-01       Impact factor: 3.179

6.  Changes in plasma profiles of matrix metalloproteinases (MMPs) and tissue inhibitors of MMPs in stress-induced cardiomyopathy.

Authors:  Essa M Essa; Michael R Zile; Robert E Stroud; Allison Rice; Richard J Gumina; Carl V Leier; Francis G Spinale
Journal:  J Card Fail       Date:  2012-06       Impact factor: 5.712

Review 7.  Membrane-associated matrix proteolysis and heart failure.

Authors:  Francis G Spinale; Joseph S Janicki; Michael R Zile
Journal:  Circ Res       Date:  2013-01-04       Impact factor: 17.367

8.  Relations of matrix remodeling biomarkers to blood pressure progression and incidence of hypertension in the community.

Authors:  Ravi Dhingra; Michael J Pencina; Peter Schrader; Thomas J Wang; Daniel Levy; Karol Pencina; Deborah A Siwik; Wilson S Colucci; Emelia J Benjamin; Ramachandran S Vasan
Journal:  Circulation       Date:  2009-02-16       Impact factor: 29.690

9.  Association of matrix metalloproteinases with MRI indices of brain ischemia and aging.

Authors:  José Rafael Romero; Ramachandran S Vasan; Alexa S Beiser; Rhoda Au; Emelia J Benjamin; Charles DeCarli; Philip A Wolf; Sudha Seshadri
Journal:  Neurobiol Aging       Date:  2009-01-06       Impact factor: 4.673

10.  Metalloproteinase-3 genotype as a predictor of cardiovascular risk in hypertensive adolescents.

Authors:  Yun Hee Lee; Tae Yeon Kim; Young Mi Hong
Journal:  Korean Circ J       Date:  2009-08-27       Impact factor: 3.243

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.